Shree Ganesh Biotech Q1 Results: Net loss widens to ₹57.32 lakh
Shree Ganesh Biotech India Ltd reported a Q1FY27 net loss of ₹57.32 lakh, down from a profit of ₹32.70 lakh in Q1FY26. Revenue rose to ₹142.99 lakh, but soaring material costs of ₹186.67 lakh drove the deficit. The results were reviewed by Bipin & Co.
*this image is generated using AI for illustrative purposes only.
Shree Ganesh Biotech reported a standalone net loss of ₹57.32 lakh for the first quarter of FY27, marking a significant reversal from the net profit of ₹32.70 lakh recorded in the corresponding quarter of the previous year. The deterioration in profitability was driven by a sharp increase in cost of materials consumed, which outpaced a modest rise in revenue from operations.
The Board of Directors approved the unaudited financial results on August 4, 2026, pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Bipin & Co. conducted a limited review of the financial statements in accordance with Standard on Review Engagements (SRE) 2410.
Financial Performance
Revenue from operations increased to ₹142.99 lakh in Q1FY27, up from ₹138.36 lakh in Q1FY26. However, this growth was insufficient to offset rising expenses. Total expenses surged to ₹232.32 lakh from ₹147.19 lakh in the prior year period. The primary driver of this cost inflation was the cost of materials consumed, which jumped to ₹186.67 lakh from ₹111.97 lakh, indicating margin pressure in the core business operations.
| Particulars | Q1FY27 (₹ Lakh) | Q1FY26 (₹ Lakh) | Change |
|---|---|---|---|
| Revenue from Operations | 142.99 | 138.36 | +3.3% |
| Cost of Materials Consumed | 186.67 | 111.97 | +66.7% |
| Other Income | 32.01 | 41.53 | -22.9% |
| Total Expenses | 232.32 | 147.19 | +57.8% |
| Net Profit / (Loss) | (57.32) | 32.70 | Turn to Loss |
Other income declined to ₹32.01 lakh from ₹41.53 lakh, further contributing to the bottom-line pressure. Employee benefit expenses also saw a notable rise, increasing to ₹5.85 lakh from ₹1.43 lakh year-on-year.
What the Numbers Show
The divergence between revenue growth and expense expansion highlights a critical operational challenge for Shree Ganesh Biotech. While top-line sales grew by approximately 3%, the cost of goods sold expanded by nearly 67%. This suggests that input cost inflation or pricing pressures have significantly eroded operating margins, turning a previously profitable quarter into a substantial loss. The company’s ability to manage material costs will be key to restoring profitability in subsequent quarters.
Historical Stock Returns for Shree Ganesh Bio-Tech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.85% | -1.79% | -1.79% | -16.67% | -30.38% | -91.31% |
Will Shree Ganesh Biotech implement price hikes for its products to offset the 66.7% surge in material costs, and how might this impact its market share?
Are there specific supply chain disruptions or raw material shortages driving the sharp increase in cost of materials consumed, and is this trend expected to persist in Q2FY27?
How does management plan to address the 309% year-on-year increase in employee benefit expenses amidst declining overall profitability?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
